Trial Profile
Efficacy of anti-RANKL human antibody (Denosumab) on prevention of osteoporosis with primary biliary cirrhosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Osteopetrosis
- Focus Therapeutic Use
- 09 Dec 2013 New trial record